Cargando…
Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response
INTRODUCTION: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia (Ph) chromosome. After the introduction of imatinib mesylate (IM) in 2000, the natural history of the disease changed. Data on the treatment of CML with IM are from randomized clini...
Autores principales: | Ferreira, Amanda Pifano Soares, Seguro, Fernanda Salles, Abdo, Andre Ramires Neder, Santos, Fernanda Maria, Maciel, Felipe Vieira Rodrigues, Nardinelli, Luciana, Giorgi, Ricardo Rodrigues, Ruiz, Antonio Roberto Lancha, Ferreira, Milton Pifano Soares, Rego, Eduardo Magalhaes, Rocha, Vanderson, Bendit, Israel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261248/ https://www.ncbi.nlm.nih.gov/pubmed/37052662 http://dx.doi.org/10.1007/s00277-023-05189-3 |
Ejemplares similares
-
Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response
por: Ferreira, Amanda Pifano Soares, et al.
Publicado: (2023) -
Determination of serum levels of imatinib mesylate in patients with
chronic myeloid leukemia: validation and application of a new analytical method to
monitor treatment compliance
por: Rezende, Vinícius Marcondes, et al.
Publicado: (2013) -
Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
por: Karolewicz, Bożena, et al.
Publicado: (2019) -
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
por: da Silva, Wellington Fernandes, et al.
Publicado: (2020) -
Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)